GlassScriptPhysician profile
Geoffrey A Mire
NPI 1114959442
$13,041.06
in general payments reported to CMS, 2019-2025
54 companies · $2,207 in 2025
The $2,207 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $1,691 · 2021: $2,107 · 2022: $1,584 · 2023: $1,886 · 2024: $1,928 · 2025: $2,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,020.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,952.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,892.99 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,104.93 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $977.61 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $857.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $517.33 | 2019-2023 | Trintellix |
| Abbvie INC. | $502.43 | 2021-2025 | |
| Corium, LLC | $372.89 | 2022-2025 | Azstarys |
| Antares Pharma, INC. | $361.75 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $335.40 | 2020-2025 | Veozah |
| Merck Sharp & Dohme LLC | $296.98 | 2019-2025 | Capvaxive, Belsomra, Gardasil 9 |
| Pfizer INC. | $277.60 | 2019-2024 | |
| Exact Sciences Corporation | $248.09 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $240.24 | 2019-2022 | |
| Noven Therapeutics, LLC | $223.49 | 2023-2025 | Xelstrym |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Mire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.